Skip to main content

Advertisement

SpringerLink
Log in

Management of renal dysfunction in multiple myeloma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Multiple myeloma is frequently associated with renal dysfunction. In addition, it has been shown that the presence of renal failure indicates a higher tumor burden and consequently more aggressive disease. Patients who are diagnosed with renal insufficiency should be aggressively treated because reversal of renal insufficiency results in survival outcomes similar to patients who have normal renal function at diagnosis. However, the presence of renal impairment could add significantly to the morbidity of these patients and make it difficult to tolerate aggressive treatment regimens. Therefore, the treatment approach to this group of patients should include a thorough understanding of the feasibility and outcomes of the various antimyeloma treatments that are available, including newer options such as thalidomide. We recommend the following sequence of treatment in newly diagnosed patients with multiple myeloma with renal insufficiency (creatinine > 2 mg/dL): correction of hypercalcemia with fulldose bisphosphonates in patients with hypercalcemia, induction therapy that may be initiated before correction of hypercalcemia with bolus VAD (vincristine 2 mg, doxorubicin 40 mg/m2, dexamethasone 40 mg on days 1–4, 9–12, and 17–20), and stem cell collection (cyclophosphamide 2.5–3 g/m2) with high-dose melphalan (140–150 mg/m2) with autologous stem cell transplant. Dialysis support should be considered whenever necessary for all newly diagnosed patients if renal function does not improve with aggressive initial therapy. For patients who develop renal insufficiency later in the course of the disease, therapeutic options need to be tailored to the patient’s treatment history, disease status, and performance status.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence-Jones proteins. N Engl J Med 1991, 324:1845–1851.

    Article  PubMed  CAS  Google Scholar 

  2. Khamlichi AA, Rocca A, Touchard G, et al.: Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. Blood 1995, 86:3655–3659.

    PubMed  CAS  Google Scholar 

  3. Pozzi C, Fogazzi GB, Banfi G, et al.: Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995, 43:281–287.

    PubMed  CAS  Google Scholar 

  4. Kyle RA: Monoclonal proteins and renal disease. Annu Rev Med 1994, 45:71–77.

    Article  PubMed  CAS  Google Scholar 

  5. Clark AD, Shetty A, Soutar R: Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999, 13:79–90.

    Article  PubMed  CAS  Google Scholar 

  6. Barlogie B, Alexanian R, Jagannath S: Plasma cell dyscrasias. JAMA 1992, 268:2946–2951.

    Article  PubMed  CAS  Google Scholar 

  7. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000, 65:175–181. A study showing the prognostic importance of reversibility of renal failure, which improves long-term survival.

    Article  PubMed  CAS  Google Scholar 

  8. Sakhuja V, Jha V, Varma S, et al.: Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000, 22:465–477.

    Article  PubMed  CAS  Google Scholar 

  9. Solling K, Solling J: Clearance of Bence-Jones proteins during peritoneal dialysis or plasmapheresis in myelomatosis associated with renal failure. Contrib Nephrol 1988, 68:259–262.

    PubMed  CAS  Google Scholar 

  10. Iggo N, Palmer AB, Severn A, et al.: Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989, 73:903–910.

    PubMed  CAS  Google Scholar 

  11. Zucchelli P, Pasquali S, Cagnoli L, et al.: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988, 33:1175–1180.

    Article  PubMed  CAS  Google Scholar 

  12. Moist L, Nesrallah G, Kortas C, et al.: Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol 1999, 19:45–50.

    Article  PubMed  CAS  Google Scholar 

  13. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J Clin Oncol 1998, 16:593–602.

    PubMed  CAS  Google Scholar 

  14. Berenson JR, Hillner BE, Kyle R, et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719–3736. The most recent American Society of Clinical Oncology guidelines for use of bisphosphonates in MM.

    Article  PubMed  Google Scholar 

  15. Misiani R, Tiraboschi G, Mingardi G, et al.: Management of myeloma kidney: an anti-light chain approach. Am J Kidney Dis 1987, 10:28–33.

    PubMed  CAS  Google Scholar 

  16. Badros A, Barlogie B, Siegel E, et al.: Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001, 114:822–829. A larger trial reporting the feasibility and possible favorable outcomes of autotransplants in patients with MM with nonreversible renal insufficiency.

    Article  PubMed  CAS  Google Scholar 

  17. Sheil AGR, Flavel S, Disney APS, et al.: Cancer development in patients progressing to dialysis and renal transplantation. Transplant Proc 1985, 17:1685–1688.

    PubMed  CAS  Google Scholar 

  18. Osterborg A, Ehrsson H, Eksborg S, et al.: Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Clin Oncol 1989, 25:899–903.

    Article  CAS  Google Scholar 

  19. Alexanian R, Dimopoulos MA: Management of multiple myeloma. Semin Hematol 1995, 32:20–30.

    PubMed  CAS  Google Scholar 

  20. Alexanian R, Dimopoulos MA, Delasalle K, et al.: Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80:887–890.

    PubMed  CAS  Google Scholar 

  21. Vacca A, Ribatti D, Roncali L, et al.: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994, 87:503–508.

    PubMed  CAS  Google Scholar 

  22. Singhal S, Mehta J, Barlogie B, et al.: Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565–1571.

    Article  PubMed  CAS  Google Scholar 

  23. Rajkumar SV, Hayman S, Gertz MA, et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002, 20:4319–4323. A key study showing the efficacy and feasibility of thalidomide and dexamethasone in newly diagnosed MM and possible use as an alternative induction therapy regimen before transplant.

    Article  PubMed  CAS  Google Scholar 

  24. Attal M, Harousseau JL, Stoppa AM, et al.: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91–97.

    Article  PubMed  CAS  Google Scholar 

  25. Attal M, Harousseau JL, Facon T, et al.: Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 94) [abstract]. Blood 2002, 100:7. A report of long-term follow-up (7 years) confirming improved OS in patients with MM who undergo double autologous transplantation in MM.

    Google Scholar 

  26. Tosi P, Zamagni E, Ronconi S, et al.: Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000, 14:1310–1313.

    Article  PubMed  CAS  Google Scholar 

  27. Lee CK, Barlogie B, Zangari M, et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant [abstract]. Blood 2002, 100:1670. A study showing the feasibility of high-dose melphalan therapy and autotransplantation in dialysis-dependent patients with MM.

    Article  CAS  Google Scholar 

  28. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000, 1:28–36. A study reporting significance of presence of abnormal renal function at the time of transplant showed a higher incidence of TRM in this group of patients.

    Article  Google Scholar 

  29. Tricot G, Gazitt Y, Leemhuis T, et al.: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high-dose therapy in multiple myeloma. Blood 1998, 91:4489–4495.

    PubMed  CAS  Google Scholar 

  30. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al.: Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000, 18:3031–3037.

    PubMed  CAS  Google Scholar 

  31. Giralt S, Weber D, Aleman A, et al.: Non-myeloablative conditioning with fludarabine/melphalan (FM) for patients with multiple myeloma [abstract]. Blood 1999, 94:1549.

    Google Scholar 

  32. Lalancette M, Rezvani K, Szydlo R, et al.: Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk multiple myeloma: the EBMT experience [abstract]. Blood 2000, 96:872.

    Google Scholar 

  33. Joshua DE, Brown RD, Gibson J: Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994, 88:667–671.

    PubMed  CAS  Google Scholar 

  34. Oivanen TM: Plateau phase in multiple myeloma: an analysis of long-term follow-up of 432 patients. Finnish Leukaemia Group. Br J Haematol 1996, 92:834–839.

    Article  PubMed  CAS  Google Scholar 

  35. Westin J, Rodjer S, Turesson I, et al.: IFN alpha-2b versus no maintenance treatment during the plateau phase on multiple myeloma: a randomized study. Br J Haematol 1995, 89:561–568.

    PubMed  CAS  Google Scholar 

  36. Browman GP, Bergsagel D, Sicheri D, et al.: Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995, 13:2354–2360.

    PubMed  CAS  Google Scholar 

  37. Brinker B, Waller E, Langston AA, et al.: Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma [abstract]. Blood 2002, 100:667.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, 53226, Milwaukee, WI, USA

    Sandeep R. Pandit MD

Authors
  1. Sandeep R. Pandit MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David H. Vesole MD, PhD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pandit, S.R., Vesole, D.H. Management of renal dysfunction in multiple myeloma. Curr. Treat. Options in Oncol. 4, 239–246 (2003). https://doi.org/10.1007/s11864-003-0025-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0025-8

Keywords

Search

Navigation